Related Experiment Video
Updated: Jun 21, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Hepatitis C virus infection and immunomodulatory therapies
Kimberly A Forde1, K Rajender Reddy
1Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Insights
Hepatitis C virus (HCV) treatment combines pegylated interferon and ribavirin, improving outcomes but not curing all patients. This review explores new immunomodulatory therapies and clinical trials for HCV infection.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis C virus (HCV) infection is a major global health issue.
- Current FDA-approved treatment involves pegylated interferon and ribavirin.
- This combination therapy can lead to sustained virologic response and reduce risks of liver disease complications.
Purpose of the Study:
- To review current immunomodulatory therapies for HCV.
- To discuss ongoing clinical trials in HCV treatment.
Main Methods:
- Literature review of immunomodulatory agents.
- Analysis of clinical trial data for HCV treatment.
Main Results:
- Pegylated interferon and ribavirin combination therapy shows efficacy but not universal cure.
- Emerging immunomodulatory therapies and clinical trials offer potential for improved HCV eradication rates.
Conclusions:
- HCV treatment remains a significant challenge, necessitating further research.
- Immunomodulatory approaches and ongoing clinical trials are crucial for advancing HCV eradication strategies.
Abstract:
Hepatitis C virus (HCV) infection remains a large-scale and significant health concern. The combination of subcutaneously administered pegylated interferon and oral ribavirin is the FDA-approved regimen for the treatment of chronic HCV infection. Combination therapy may result in a sustained virologic response leading to HCV eradication, with a reduction in risk for cirrhosis, hepatic decompensation, and hepatocellular carcinoma. However, the combination of PEG-IFN and ribavirin does not universally result in cure in all patients who undergo treatment. In this article, the authors discuss immunomodulatory therapies and clinical trials in the treatment of HCV infection.
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Tumor Immunotherapy
Cytomegalovirus Disease
Viral Hepatitis I: Introduction
